There are currently 229 clinical trials in Spokane, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including Cancer Care Northwest - Spokane South, Providence Sacred Heart Medical Center and Children's Hospital, Evergreen Hematology and Oncology, PS and Premier Clinical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Impella RP Flex with Smart Assist
NCT06637644
Recruiting
To capture observational data of the Abiomed Impella RP Flex in a real-world setting.
Gender:
ALL
Ages:
All
Trial Updated:
10/09/2024
Locations: Providence Sacred Heart Medical Center, Spokane, Washington
Conditions: Right Ventricular (RV) Dysfunction
Register for Updates
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2024
Locations: Research Site, Spokane, Washington
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Velocity Clinical Research, Spokane, Washington
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283
Recruiting
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonar... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/23/2024
Locations: Providence Medical Group, Cystic Fibrosis Clinic, Spokane, Washington
Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Register for Updates
Automated Reinforcement Management Systems, Phase II
NCT06456905
Recruiting
The Automated Reinforcement Management Systems Phase II (ARMS II) study is a phase II trial is a randomized controlled, non-medicated assisted trial to determine the effectiveness of Contingency Management (CM) treatment for reducing alcohol drinking among adults who want to quit or reduce their alcohol consumption.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/09/2024
Locations: Washington State University, Spokane, Washington
Conditions: Alcohol Use Disorder
Register for Updates
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
NCT05134857
Recruiting
A phase II randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of zonisamide (ZON) to decrease alcohol use among treatment-seeking adults with an alcohol use disorder (AUD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/09/2024
Locations: Washington State University, Spokane, Washington
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane, Washington +1 locations
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Defining Treatment Outcomes and Genetic Architecture in Idiopathic Toe Walking*
NCT06305689
Recruiting
To compare and contrast the clinical, gait and parent-reported outcomes following either non-operative (casting) or operative treatment for children with idiopathic toe walking (ITW) and determine whether there are specific genes associated with ITW.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/23/2024
Locations: Shriners Children's Spokane, Spokane, Washington
Conditions: Idiopathic Toe Walking
Register for Updates
Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
NCT04783558
Recruiting
Most newborns experiencing Neonatal Abstinence Syndrome (NAS) require non-pharmacologic care, which entails, most importantly, maternal involvement with her newborn. To facilitate positive maternal-newborn interactions, mothers need to learn effective caregiving NAS strategies while they are pregnant, yet, an enormous gap exists in the early education of mothers on the symptoms and progression of NAS, in part because no interventions exist to prepare future mothers for the challenges of caring f... Read More
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
07/22/2024
Locations: Washington State University, Spokane, Washington
Conditions: Neonatal Abstinence Syndrome, Opioid-use Disorder
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Cancer Care Northwest - Spokane South, Spokane, Washington +7 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
NCT05181891
Recruiting
Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have initiated pharmacotherapy (varenicline; VC) for smoking cessation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2024
Locations: Washington State University, Spokane, Washington
Conditions: Alcohol Use Disorder (AUD), Nicotine Use Disorder
Register for Updates
Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
NCT04069312
Recruiting
A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/06/2024
Locations: Providence Health and Services, Spokane, Washington
Conditions: Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
Register for Updates